Literature DB >> 11579619

Molecular neurobiology of addiction.

E J Nestler1.   

Abstract

Addiction can be viewed as a form of drug-induced neural plasticity. One of the best established molecular mechanisms of addiction is the upregulation of the cAMP second messenger pathway, which occurs in many neuronal cell types in response to chronic administration of opiates or other drugs of abuse. This upregulation and the resulting activation of the transcription factor CREB appear to mediate aspects of tolerance and dependence. In contrast, induction of another transcription factor, termed delta FosB, exerts the opposite effect and may contribute to sensitized responses to drug exposure. Knowledge of these mechanisms could lead to more effective treatments for addictive disorders.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11579619     DOI: 10.1080/105504901750532094

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  129 in total

Review 1.  A behavioral/systems approach to the neuroscience of drug addiction.

Authors:  Francis J White
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

2.  G-protein-gated potassium channels containing Kir3.2 and Kir3.3 subunits mediate the acute inhibitory effects of opioids on locus ceruleus neurons.

Authors:  Maria Torrecilla; Cheryl L Marker; Stephanie C Cintora; Markus Stoffel; John T Williams; Kevin Wickman
Journal:  J Neurosci       Date:  2002-06-01       Impact factor: 6.167

3.  Effect of acamprosate on magnetic resonance spectroscopy measures of central glutamate in detoxified alcohol-dependent individuals: a randomized controlled experimental medicine study.

Authors:  John C Umhau; Reza Momenan; Melanie L Schwandt; Erick Singley; Mariel Lifshitz; Linda Doty; Lauren J Adams; Valentina Vengeliene; Rainer Spanagel; Yan Zhang; Jun Shen; David T George; Daniel Hommer; Markus Heilig
Journal:  Arch Gen Psychiatry       Date:  2010-10

4.  Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons.

Authors:  Reuben Saba; Peter H Störchel; Ayla Aksoy-Aksel; Frauke Kepura; Giordano Lippi; Tim D Plant; Gerhard M Schratt
Journal:  Mol Cell Biol       Date:  2011-12-05       Impact factor: 4.272

Review 5.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

6.  Immediate early gene expression reveals interactions between social and nicotine rewards on brain activity in adolescent male rats.

Authors:  Ryan M Bastle; Natalie A Peartree; Julianna Goenaga; Kayla N Hatch; Angela Henricks; Samantha Scott; Lauren E Hood; Janet L Neisewander
Journal:  Behav Brain Res       Date:  2016-07-18       Impact factor: 3.332

7.  A new approach to researching the etiology of cannabis use disorder: integrating transmissible and nontransmissible risk within a developmental framework.

Authors:  Ralph Tarter; Levent Kirisci; Maureen Reynolds
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

8.  Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus.

Authors:  Ming Li; Wei He; Alexa Mead
Journal:  Behav Pharmacol       Date:  2009-02       Impact factor: 2.293

9.  Knockdown of tyrosine hydroxylase in the nucleus of the solitary tract reduces elevated blood pressure during chronic intermittent hypoxia.

Authors:  Chandra Sekhar Bathina; Anuradha Rajulapati; Michelle Franzke; Kenta Yamamoto; J Thomas Cunningham; Steve Mifflin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-09-18       Impact factor: 3.619

10.  Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice.

Authors:  Lu-lu Yu; Xue-yi Wang; Mei Zhao; Yu Liu; Yan-qin Li; Fang-qiong Li; Xiaoyi Wang; Yan-xue Xue; Lin Lu
Journal:  Psychopharmacology (Berl)       Date:  2009-01-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.